
    
      Patients enrolled in AP-003-C Main Study will be offered the option to roll-over to the open
      label extension study at the final visit of the Main Study (Week 12).

      Approximately 171 subjects with knee pain due to severe osteoarthritis of the knee (KL IV)
      may enroll in the 40-week OLE study. The OLE Study allows for a 60-day screening window from
      Week 12 of the Main Study for enrollment in the Extension study. Extension study visits will
      include 9 visits: Week 12 in-office visit (Day 84± 60 days), a 24-hour post-injection
      follow-up call, Week 24 in-office visit (Day 168 ± 7 days), a 24-hour, post-injection
      follow-up call, Week 36 in-office visit (Day 252 ± 7 days), a 24-hour, post-injection
      follow-up call, Week 48 in-office visit (Day 336 ± 7 days ), a 24-hour, post-injection
      follow-up call, and a Week 52 final visit (Day 364 ± 7 days ).
    
  